Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. (June 2015)

• Record Type: Journal Article
• Authors: Huang, Zebo; Wu, Yinxia; Zhou, Xin; Qian, Jiaqi; Zhu, Wei; Shu, Yongqian; Liu, Ping
• Is Part Of: Future oncology. Volume 11:Number 11(2015)
• Page Start: 1687
• Page End: 1699
• Publication Date: 2015-06
• Subjects: clinical trials -- mTOR inhibitor -- solid tumor; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.70
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : The common dysregulation of the mTOR signaling pathway in tumor cells makes it a key target in oncotherapy. To better understand the effects of mTOR inhibitors, we analyzed 32 published clinical trials on solid tumors other than renal cell cancer, neuroendocrine tumors and metastatic breast cancer, for mTOR inhibitors are already approved by the US FDA to treat the three cancers. A lack of therapeutic effects was observed when mTOR inhibitors were used as a single agent. When combined with other agents, mTOR inhibitors still lacked sufficient clinical activity or just had minimal activity. More studies are required to better understand the clinically effects of mTOR inhibitors and the development of novel mTOR inhibitors is absolutely necessary.